Articles

Results of KEYNOTE-585 are consistent with those from the MATTERHORN study. Read More ›

The FDA recently announced the publication of an article reviewing 50 years of the FDA’s experience with clinical research related to the use of cannabis in drug development. Read More ›

In the evolving landscape of healthcare, the integration of music and mindfulness into clinical practice represents a frontier of therapeutic innovation, particularly for patients undergoing rigorous treatments such as allogeneic stem cell transplants. Read More ›

Using these 5 strategies will contribute to timely patient care and efficient office operations. Read More ›

Oncology Practice Management and the Practice Management Institute are proud to present our exclusive series on optimizing the patient experience. In next month’s edition, we present strategies to address scheduling challenges. Read More ›

A subcutaneous form of nivolumab has the potential to be more convenient and most easily tolerated. Read More ›

For the first time, an adjuvant treatment has led to a survival benefit in clear cell renal cell carcinoma (ccRCC). Data from the multicenter phase 3 KEYNOTE-564 study demonstrate that adjuvant pembrolizumab led to a 38% lower risk of death compared with placebo among patients with ccRCC who had a high risk of recurrence after surgery. The findings were presented by Toni K. Choueiri, MD, at the 2024 ASCO Genitourinary Cancers Symposium. Read More ›

The combination of cabozantinib and atezolizumab improved radiographic progression-free survival (rPFS) versus a switch to a second novel hormonal agent (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a first NHT, according to findings from the phase 3 CONTACT-02 trial. Read More ›